Chen, J.; Pan, X.; Duro Castano, A.; Cai, H.; Guo, B.; Liu, X.; Yu, Y.; Lui, S.; Luo, K.; Ke, B.; Ruiz-Perez, L.; Wei, X.; Gong, Q.; Tian, X.; Battaglia, G.

We have developed a new method for treating Alzheimer's disease (AD) by targeting the LRP1 receptor at the blood-brain barrier (BBB) using a nanoscopic multivalent scaffold decorated with LRP1 targeting peptides. Our experiments on AD model mice have demonstrated that this treatment significantly reduces amyloid-{beta} (A{beta}) deposits and improves cognitive function. This study introduces a new approach to drug design that combines multivalent targeting with controlling membrane trafficking using the same tools for nanocarrier design, creating a novel therapeutic intervention. In doing so, we emphasize the crucial role that the BBB plays in AD pathogenesis, highlighting the vital importance of LRP1-mediated A{beta} clearance.